百济神州在2024年交出了一份亮眼的业绩成绩单,引发了市场广泛关注,盘中股价一度大涨5.51%。
公司主力产品百悦泽(泽布替尼)和百泽安(替雷利珠单抗)在全球市场继续保持强劲增长。尤其是百悦泽在美国市场销售额大幅攀升107.5%,全年销售额突破20亿美元,这让市场对其未来增长空间持续看好。
得益于新药放量,百济神州2024年实现营收38.1亿美元,同比大增55%,经营亏损较上年也出现明显收窄。值得注意的是,公司还首次在年度经调整的营业利润指标上实现盈利,实现扭亏为盈的重要转折,预示着公司正在迈向真正的盈利拐点。
而对于2025年,百济神州给出了年收入指引为49亿至53亿美元,并一再重申全年将实现经营利润为正、且经营活动将产生正现金流。市场对此表示充分认可,普遍看好公司的盈利预期已不远。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.